Sim Farar Joins BioSig Technologies Advisory Board

Santa Monica, CA, May 08, 2018 -- BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that Sim Farar, Los Angeles based businessman and political adviser, joined the Advisory Board of the Company.  

Mr. Farar brings to BioSig over 30 years of experience in both public and private sectors. From 1999 – 2000, following presidential appointment and confirmation by the U.S. Senate, Mr. Farar served as the United States Representative to the 54th General Assembly at the United Nations.  In February 2011, again following presidential appointment and confirmation by the U.S. Senate, Mr. Farar was named as a Commissioner to the U.S. Advisory Commission on Public Diplomacy, which is charged with appraising U.S. Government activities intended to understand, inform and influence foreign publics. The Commission reports to the President, the Secretary of State, and Congress. He currently serves as Chair of that Commission. From 2001 to 2005, he also served on the Board of Fire and Police Pension Commissioners of the City of Los Angeles.

In the private sector, Mr. Farar has served as CEO, Chairman of the Board, Director and consultant to a number of companies, including JDF Investment Co. LLC, IFC Financial Services Corp, and has served as an adviser to several other private and public companies. 

“In addition to his commercial success, Sim brings very impressive achievements and deep understanding of public policy sector on regional, national and global levels. With his unique skills, innovative thinking and the strength of his relationships in our home town of Los Angeles, Sim is an invaluable addition to our Advisory Board, ” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

The goal of the newly formed Advisory Board is to advise the leadership of BioSig on a range of subjects, including financing, strategy, marketing, government affairs, partnerships and M&A. Current Members of the Board include California based Mr. Kent Bennett Williams, CEO and Principal at Vista Asset Management, LLC, and Texas based Dr. Ramachandra Malya, Medical Director and consulting nephrologist.

“As someone who followed BioSig’s efforts since the very beginning, I have always been impressed by the Company’s progress and team’s dedication to address unmet clinical needs on a global scale. I’m pleased to join the team at this crucial time in the Company’s life cycle and lend my support to further enhance BioSig’s performance,” commented Mr. Farar.

About BioSig Technologies
BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System.  The technology has been developed to address an unmet need in a large and growing market.

The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and is working toward FDA 510(k) clearance for the PURE EP(TM) System.

Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Registration Statement on Form S-1 (File No. 333-223298), as declared effective on March 26, 2018, its  Annual Report on Form 10-K/A filed with the SEC on March 26, 2018 and its Quarterly Report on Form 10-Q as filed with the SEC on May 4, 2018. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 

Contact:
Natasha Russkina
BioSig Technologies, Inc. 
VP Business Development & Corporate Finance 
[email protected]
+41 (0) 76 823 7527